Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 1/2 4Phase 2 3Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Non-Hodgkin 17Lymphoma, Follicular 14Lymphoma, Mantle-Cell 9Lymphoma 6Lymphoma, B-Cell, Marginal Zone 5Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 2Leukemia 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Leukemia, B-Cell 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Chromosome 17 deletion 1

Interventions

Rituximab 14pirtobrutinib 6ibrutinib 4Vincristine 4Doxorubicin 4Prednisone 3Cytarabine 3Cyclophosphamide 3zanubrutinib 2acalabrutinib 2Methotrexate 2Etoposide 2Bendamustine Hydrochloride 2venetoclax 1tositumomab I-131 1idelalisib 1ibritumomab tiuxetan 1etoposide phosphate 1entecavir 1cirmtuzumab 1axicabtagene ciloleucel 1VAP-cyclo protocol 1Tenofovir 1Radiotherapy 1Melphalan 1Ifosfamide 1Gemcitabine 1Everolimus 1Drug Therapy 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell × Bendamustine Hydrochloride × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05023980 2026-01-22

BRUIN CLL-313

Eli Lilly and Company

Phase 3 Active not recruiting
309 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡